Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David C Dale

Showing results (81-90 of 142) with videos related to

Pageof 15
Sort By:
Cancer|August 13, 2009
Dose intensity and hematologic toxicity in older breast cancer patients receiving systemic chemotherapyMichelle Shayne, Eva Culakova, Debra Wolff, et al.
European Journal of Haematology|October 26, 2011
The cellular and molecular mechanisms for neutropenia in Barth syndromeVahagn Makaryan, Willem Kulik, Frederic M Vaz, et al.
Cancer|August 21, 2007
Dose intensity and hematologic toxicity in older cancer patients receiving systemic chemotherapyMichelle Shayne, Eva Culakova, Marek S Poniewierski, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|March 6, 2008
Risk and timing of neutropenic events in adult cancer patients receiving chemotherapy: the results of a prospective nationwide study of oncology practiceJeffrey Crawford, David C Dale, Nicole M Kuderer, et al.
Journal of Geriatric Oncology|January 30, 2014
Risk factors for in-hospital mortality and prolonged length of stay in older patients with solid tumor malignanciesMichelle Shayne, Eva Culakova, Marek S Poniewierski, et al.
British Journal of Haematology|September 25, 2009
Prevalence of mutations in ELANE, GFI1, HAX1, SBDS, WAS and G6PC3 in patients with severe congenital neutropeniaJun Xia, Audrey A Bolyard, Elin Rodger, et al.
Cancer Medicine|March 27, 2015
Assessing patients' risk of febrile neutropenia: is there a correlation between physician-assessed risk and model-predicted risk?Gary H Lyman, David C Dale, Jason C Legg, et al.
Blood|January 18, 2003
Retraction. Neutrophil elastase mutations in severe congenital neutropenia patients of the original Kostmann familyAndrew A Aprikyan, Goran Carlsson, Steve Stein, et al.
Cancer|April 22, 2011
Predicting individual risk of neutropenic complications in patients receiving cancer chemotherapyGary H Lyman, Nicole M Kuderer, Jeffrey Crawford, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 14, 2010
Acute myeloid leukemia or myelodysplastic syndrome in randomized controlled clinical trials of cancer chemotherapy with granulocyte colony-stimulating factor: a systematic reviewGary H Lyman, David C Dale, Debra A Wolff, et al.
Pageof 15

Showing results (81-90 of 142) with videos related to

Sort By:
Pageof 15
Cancer|August 13, 2009
Dose intensity and hematologic toxicity in older breast cancer patients receiving systemic chemotherapyMichelle Shayne, Eva Culakova, Debra Wolff, et al.
European Journal of Haematology|October 26, 2011
The cellular and molecular mechanisms for neutropenia in Barth syndromeVahagn Makaryan, Willem Kulik, Frederic M Vaz, et al.
Cancer|August 21, 2007
Dose intensity and hematologic toxicity in older cancer patients receiving systemic chemotherapyMichelle Shayne, Eva Culakova, Marek S Poniewierski, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|March 6, 2008
Risk and timing of neutropenic events in adult cancer patients receiving chemotherapy: the results of a prospective nationwide study of oncology practiceJeffrey Crawford, David C Dale, Nicole M Kuderer, et al.
Journal of Geriatric Oncology|January 30, 2014
Risk factors for in-hospital mortality and prolonged length of stay in older patients with solid tumor malignanciesMichelle Shayne, Eva Culakova, Marek S Poniewierski, et al.
British Journal of Haematology|September 25, 2009
Prevalence of mutations in ELANE, GFI1, HAX1, SBDS, WAS and G6PC3 in patients with severe congenital neutropeniaJun Xia, Audrey A Bolyard, Elin Rodger, et al.
Cancer Medicine|March 27, 2015
Assessing patients' risk of febrile neutropenia: is there a correlation between physician-assessed risk and model-predicted risk?Gary H Lyman, David C Dale, Jason C Legg, et al.
Blood|January 18, 2003
Retraction. Neutrophil elastase mutations in severe congenital neutropenia patients of the original Kostmann familyAndrew A Aprikyan, Goran Carlsson, Steve Stein, et al.
Cancer|April 22, 2011
Predicting individual risk of neutropenic complications in patients receiving cancer chemotherapyGary H Lyman, Nicole M Kuderer, Jeffrey Crawford, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 14, 2010
Acute myeloid leukemia or myelodysplastic syndrome in randomized controlled clinical trials of cancer chemotherapy with granulocyte colony-stimulating factor: a systematic reviewGary H Lyman, David C Dale, Debra A Wolff, et al.
Pageof 15